Cymba conchae, sham trouble, and how to read taVNS papers.
Ear-clip 'vagus nerve' devices are being studied for many things — sleep, anxiety, long COVID, pain — but most uses are investigational, not proven, and studies use very different settings, durations, and ear locations. If you want to try one, do it with realistic expectations and don't replace medical care with it.
taVNS is generally safe (mild, transient AEs: skin irritation, headache, dizziness) but protocols are not standardized. Treat consumer devices with skepticism; counsel patients to avoid replacing standard care. When asked, frame as low-harm experimentation with uncertain benefit, and document patient preferences.
Critical appraisal: sham earlobe placement may not be physiologically inert (the earlobe has Arnold-adjacent fibers in some individuals). Demand pre-registration, dose justification, blinding checks, and biomarker (e.g., pupil dilation, P300, salivary alpha-amylase) verification of stimulation engagement.
taVNS spans Tiers 3–5: CE-marked medical devices, investigational platforms, and consumer wellness gadgets share hardware family but not evidence.
They differ in electrode placement (cymba vs tragus vs earlobe), waveform, frequency, current, and duty cycle — and most consumer devices have no clinical evidence at all.
Short patient encounters that test your judgment, not your recall. Pick the most defensible response, then reveal the rationale and a sample coaching script you could actually say at the bedside.
A colleague forwards a small open-label taVNS study claiming benefit in long COVID and asks whether you'd recommend the protocol.
A patient says her insurance won't cover the taVNS device 'her doctor prescribed' — actually a $99 consumer ear-clip from Amazon.
A patient with tinnitus reads about 'paired VNS for tinnitus' (Serenity / MicroTransponder) and assumes a consumer ear-clip is the same thing.